Lateral flow assays for non-diagnostic analytes

Abstract

Methods of determining whether a non-diagnostic analyte is present in a non-diagnostic sample are provided. Aspects of the methods include applying a non-diagnostic sample to a sample receiving region of a lateral flow assay device and reading a detection region to determine whether a non-diagnostic analyte is present in the non-diagnostic sample. Also provided are kits that find use in practicing methods of the invention.

1 - 41 . (canceled) 
     
     
         42 . A method of determining whether a recombinant virus is generated from a packaging cell line, the method comprising:
 (a) applying a sample of a viral vector packaging supernatant to a sample receiving region of a test lateral flow assay device; and   (b) reading a detection region of the test lateral flow assay device to determine whether the recombinant virus is present in the sample, wherein the detection region comprises a capture binding member that specifically binds to the recombinant virus.   
     
     
         43 . The method according to  claim 42 , wherein the recombinant virus is selected from the group consisting of a retrovirus, a baculovirus and an adenovirus. 
     
     
         44 . The method according to  claim 43 , wherein the recombinant virus is a retrovirus. 
     
     
         45 . The method according to  claim 44 , wherein the retrovirus is a lentivirus. 
     
     
         46 . The method according to  claim 42 , wherein the method further comprises applying a control sample to a sample receiving region of a control lateral flow assay device and reading a detection region of the control lateral flow assay device, wherein the control lateral flow assay device is identical to the test lateral flow assay device. 
     
     
         47 . The method according to  claim 42 , wherein the method qualitatively determines whether the recombinant virus is present in the sample. 
     
     
         48 . The method according to  claim 42 , wherein the method quantitatively determines whether the recombinant virus is present in the sample. 
     
     
         49 . The method according to  claim 42 , wherein the detection region comprises two or more distinct capture probe regions. 
     
     
         50 . The method according to  claim 42 , wherein the method is a method of determining whether two or more different analytes of the recombinant virus are present in the sample. 
     
     
         51 . The method according to  claim 50 , wherein the test lateral flow assay device comprises a single sample receiving region and a detection region comprising capture probes for each of the two or more different analytes. 
     
     
         52 . The method according to  claim 42 , wherein the test lateral flow assay device comprises two or more lanes each comprising a separate sample receiving region and detection region. 
     
     
         53 . The method according to  claim 52 , wherein the detection region of each lane detects the same recombinant virus. 
     
     
         54 . The method according to  claim 52 , wherein the detection region of each lane detects a different recombinant virus. 
     
     
         55 . The method according to  claim 42 , wherein the test lateral flow assay device comprises a reporter binding member positioned between the sample receiving region and the detection region, wherein the reporter binding member specifically binds to the recombinant virus. 
     
     
         56 . The method according to  claim 55 , wherein the reporter binding member binds to the recombinant virus at a location that is different from the location to which the capture probe binds. 
     
     
         57 . The method according to  claim 55 , wherein the reporter binding member comprises a label selected from the group consisting of a fluorescent dye, radio label, enzyme, and colorimetric label. 
     
     
         58 . The method according to  claim 42 , wherein the test lateral flow assay device comprises a control region downstream from the detection region. 
     
     
         59 . The method according to  claim 42 , wherein the capture binding member is selected from the group consisting of: an antibody, a protein, a peptide, and a hapten. 
     
     
         60 . The method according to  claim 42 , wherein:
 the method further comprises applying a control sample to a sample receiving region of a control lateral flow assay device and reading a detection region of the control lateral flow assay device, wherein the control lateral flow assay device is identical to the test lateral flow assay device.   
     
     
         61 . The method according to  claim 42 , wherein the method further comprises producing the viral vector packaging supernatant.